文献速递肝病

非酒精性脂肪性肝病的性别差异:最新进展与研究空白识别

Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps.
PubMed 文献 · Hepatology · 2019-09-23

本文综述了非酒精性脂肪性肝病(NAFLD)性别差异的现有知识,指出育龄期男性患病率和严重程度高于女性,绝经后女性发病率升高提示雌激素具有保护作用;动物模型可重现患者的性别差异。作者认为多数临床和流行病学研究未恰当分析性别差异,建议临床试验按性别、年龄、生殖阶段和合成激素使用设计,以评估药物疗效和安全性。

要点

  • 育龄期男性NAFLD患病率和严重程度高于女性,绝经后女性发病率升高,提示雌激素具有保护作用。
  • 男性动物模型的脂肪变性和脂肪性肝炎更严重,促炎/促纤维化细胞因子更多,肝脏肿瘤发生率更高。
  • 作者建议临床试验按性别、年龄、生殖阶段(即绝经)和合成激素使用设计,以评估药物疗效和安全性。

核心结论

  • NAFLD在患病率、危险因素、纤维化和临床结局方面确实存在性别差异,提示性别虽尚未纳入,但未来实践指南可能会考虑性别。
  • 需要在NAFLD的临床研究和基因关联研究中充分考虑性别差异、性激素/绝经状态、年龄和其他生殖信息,以填补当前空白并实施针对NAFLD患者的精准医学。

研究设计与样本

  • 本文为综述,总结了当前关于NAFLD性别差异的知识,识别研究空白并讨论未来研究的重要考虑因素。

主要发现

  • 育龄期男性NAFLD患病率和严重程度高于女性,而绝经后女性NAFLD发生率更高,提示雌激素具有保护作用。
  • NAFLD的主要危险因素也存在性别差异。
  • 总体而言,NAFLD动物模型重现了患者中观察到的性别差异,雄性比雌性受试者脂肪变性和脂肪性肝炎更严重、促炎/促纤维化细胞因子更多、肝脏肿瘤发生率更高。
  • 基于计算机建模,女性和男性肝脏在代谢上不同,具有独特的调节因子调节性别特异性代谢结局。
  • 对文献的分析显示,大多数已发表的临床和流行病学研究未能恰当地分析性别差异。

关键数值与推荐

  • 作者建议临床试验应按性别、年龄、生殖阶段(即绝经)和合成激素使用设计,以测试药物疗效和安全性。

临床怎么用

  • 作者认为,鉴于性别差异数据缺乏以及当前NAFLD治疗靶点相关通路的调节因子存在性别差异,临床试验应按性别、年龄、生殖阶段(即绝经)和合成激素使用设计,以测试药物疗效和安全性。
  • 作者认为,需要在NAFLD的临床研究和基因关联研究中充分考虑性别差异、性激素/绝经状态、年龄和其他生殖信息,以填补当前空白并实施精准医学。

局限性

  • 大多数已发表的临床和流行病学研究未能恰当地分析性别差异。
  • 关于性别差异的数据缺乏。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite tremendous research advancements in nonalcoholic fatty liver disease (NAFLD), our understanding of sex differences in NAFLD remains insufficient. This review summarizes the current knowledge on sex differences in NAFLD, identifies gaps, and discusses important considerations for future research. The prevalence and severity of NAFLD are higher in men than in women during the reproductive age. However, after menopause, NAFLD occurs at a higher rate in women, suggesting that estrogen is protective. Sex differences also exist for the major risk factors of NAFLD. In general, animal models of NAFLD recapitulate the sex differences observed in patients, with more severe steatosis and steatohepatitis, more proinflammatory/profibrotic cytokines, and a higher incidence of hepatic tumors in male than female subjects. Based on computer modeling, female and male livers are metabolically distinct with unique regulators modulating sex-specific metabolic outcomes. Analysis of the literature reveals that most published clinical and epidemiological studies fail to examine sex differences appropriately. Considering the paucity of data on sex differences and the knowledge that regulators of pathways relevant to current therapeutic targets for NAFLD differ by sex, clinical trials should be designed to test drug efficacy and safety according to sex, age, reproductive stage (i.e., menopause), and synthetic hormone use. Conclusion: Sex differences do exist in the prevalence, risk factors, fibrosis, and clinical outcomes of NAFLD, suggesting that, while not yet incorporated, sex will probably be considered in future practice guidelines; adequate consideration of sex differences, sex hormones/menopausal status, age, and other reproductive information in clinical investigation and gene association studies of NAFLD are needed to fill current gaps and implement precision medicine for patients with NAFLD.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Lonardo A, Nascimbeni F, Ballestri S, et al. Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps. Hepatology. 2019. PMID: 30924946. doi:10.1002/hep.30626

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。